NANOVIRICIDES Business Summary

NanoViricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company that operates as a pioneer in host-mimetic nanomedicine, focusing on the development of broad-spectrum antiviral therapeutics. The company currently generates no revenue from product sales, as it remains in the development phase; instead, its business model centers on the future licensing and commercialization of its proprietary TheraCour® nanomedicine platform. Operations are primarily funded through equity financing, including at-the-market (ATM) facilities and private placements, supplemented by a $3 million line of credit from its founder. Its primary business segments are categorized by therapeutic focus, including respiratory viruses (Measles, MPox, RSV, and Influenza), the HerpeCide™ program for shingles and cold sores, and specialty programs for HIV and Hepatitis. NNVC competes with biotechnology firms such as OKYO Pharma, MediciNova, Scilex, and BioHarvest Sciences, positioning itself as a niche innovator whose "nanomachine" approach physically neutralizes viruses to prevent the mutational escape common in traditional antiviral treatments. The leadership team is anchored by co-founder Dr. Anil R. Diwan, who serves as the Executive Chairman, President, and CEO. Dr. Diwan is the primary inventor of the company's core technology and holds a PhD from Rice University and a B.Tech from the Indian Institute of Technology, Bombay. He is supported by CFO Meeta Vyas, a seasoned executive who was the first Indian woman to serve as CEO of a publicly traded U.S. corporation and holds an MBA from Columbia University and a BS from MIT. The technical leadership includes Dr. Jayant Tatake, Vice President of R&D, an organic chemist with over 25 years of experience in pharmaceutical scale-up. The company’s Board of Directors features high-profile members such as former U.S. Congressman Todd Rokita and former Pfizer executive Dr. Makarand Jawadekar. Notable institutional investors include The Vanguard Group, BlackRock, and Renaissance Technologies, reflecting a stable base of institutional interest despite the company's pre-revenue status.